Zymeworks (ZYME) Competitors $14.18 -0.18 (-1.25%) As of 01:24 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsSEC FilingsShort InterestTrendsBuy This Stock ZYME vs. ACAD, PCVX, AAPG, ACLX, ADMA, ZLAB, AKRO, TLX, PTCT, and LNTHShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include ACADIA Pharmaceuticals (ACAD), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), Arcellx (ACLX), ADMA Biologics (ADMA), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Telix Pharmaceuticals (TLX), PTC Therapeutics (PTCT), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Its Competitors ACADIA Pharmaceuticals Vaxcyte Ascentage Pharma Group International Arcellx ADMA Biologics Zai Lab Akero Therapeutics Telix Pharmaceuticals PTC Therapeutics Lantheus Zymeworks (NASDAQ:ZYME) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Which has stronger valuation & earnings, ZYME or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$76.30M13.97-$122.69M-$0.97-14.62ACADIA Pharmaceuticals$957.80M4.45$226.45M$1.3318.99 Is ZYME or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 21.80% compared to Zymeworks' net margin of -59.96%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Zymeworks' return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-59.96% -21.59% -16.52% ACADIA Pharmaceuticals 21.80%14.69%9.41% Do insiders & institutionals believe in ZYME or ACAD? 92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor ZYME or ACAD? In the previous week, ACADIA Pharmaceuticals had 17 more articles in the media than Zymeworks. MarketBeat recorded 19 mentions for ACADIA Pharmaceuticals and 2 mentions for Zymeworks. ACADIA Pharmaceuticals' average media sentiment score of 0.82 beat Zymeworks' score of -0.22 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ZYME or ACAD? Zymeworks has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Do analysts recommend ZYME or ACAD? ACADIA Pharmaceuticals has a consensus target price of $28.88, indicating a potential upside of 14.31%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Zymeworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ACADIA Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.61 SummaryACADIA Pharmaceuticals beats Zymeworks on 15 of the 17 factors compared between the two stocks. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworks IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$1.07B$2.08B$2.56B$9.76BDividend YieldN/A13.69%2.55%4.10%P/E Ratio-14.6212.5022.1625.25Price / Sales13.972,739,392.2678.7488.19Price / CashN/A19.3423.4628.45Price / Book2.883.3836.885.99Net Income-$122.69M-$440.16M$31.01M$265.34M7 Day Performance13.99%0.83%0.82%2.73%1 Month PerformanceN/A1.18%0.92%1.47%1 Year PerformanceN/A8.97%29.02%25.31% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworks0.1256 of 5 stars$14.18-1.3%N/AN/A$1.07B$76.30M-14.62460News CoverageAnalyst UpgradeGap UpACADACADIA Pharmaceuticals3.9004 of 5 stars$25.33+3.3%$28.88+14.0%+64.5%$4.27B$957.80M19.05510Analyst UpgradePCVXVaxcyte2.1517 of 5 stars$32.70+4.0%$136.50+317.4%-58.6%$4.25BN/A-7.96160AAPGAscentage Pharma Group InternationalN/A$44.99+6.0%N/AN/A$4.18B$134.35M0.00600News CoverageGap UpACLXArcellx1.8537 of 5 stars$74.08+3.1%$114.31+54.3%+13.5%$4.11B$107.94M-21.6680News CoverageADMAADMA Biologics4.4211 of 5 stars$16.99+0.1%$27.67+62.8%-3.2%$4.06B$426.45M19.76530News CoveragePositive NewsZLABZai Lab2.56 of 5 stars$35.73+2.3%$57.22+60.1%+109.2%$3.97B$398.99M-17.511,869AKROAkero Therapeutics3.9341 of 5 stars$49.38-1.4%$81.57+65.2%+98.6%$3.95BN/A-24.6930News CoverageAnalyst UpgradeTLXTelix PharmaceuticalsN/A$11.54+5.0%$22.33+93.5%N/A$3.91B$516.72M0.00N/AUpcoming EarningsHigh Trading VolumePTCTPTC Therapeutics4.4444 of 5 stars$48.82+0.2%$70.15+43.7%+46.1%$3.88B$806.78M7.001,410LNTHLantheus4.7268 of 5 stars$54.18-0.5%$105.50+94.7%-42.9%$3.68B$1.53B14.41700 Related Companies and Tools Related Companies ACADIA Pharmaceuticals Alternatives Vaxcyte Alternatives Ascentage Pharma Group International Alternatives Arcellx Alternatives ADMA Biologics Alternatives Zai Lab Alternatives Akero Therapeutics Alternatives Telix Pharmaceuticals Alternatives PTC Therapeutics Alternatives Lantheus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYME) was last updated on 8/18/2025 by MarketBeat.com Staff From Our Partners"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access